Patents by Inventor Chongjun Yuan

Chongjun Yuan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biflavone compound against I-type herpes simplex virus, and preparation method therefor and use thereof
    Patent number: 12122756
    Abstract: A biflavone compound against an I-type herpes simplex virus, and a preparation method therefor and the use thereof. The bioflavone compound is a compound of formula I, or a crystal form thereof, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a hydrate thereof, or a prodrug thereof. The biflavone compound has a good inhibitory effect on the I-type herpes simplex virus, has a significant effect on the replication and direct inactivation of the virus, and is dose dependent. The compound is also effective in preventing and/or treating viral keratitis caused by the I-type herpes simplex virus. The compound has good water solubility and low toxicity. It can be prepared into an external preparation for resisting the I-type herpes simplex virus, such as eye drops and eye ointment, and external ointments, creams, gel agents, film agents, film-coating agents, etc.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: October 22, 2024
    Assignees: SICHUAN ACADEMY OF SCIENCES OF TRADITIONAL CHINESE MEDICINE
    Inventors: Lei Zhang, Chongjun Yuan, Mingming Yuan, Shuai Chen, Wei Yang, Sen Luo, Xia Wu
  • BIFLAVONE COMPOUND AGAINST I-TYPE HERPES SIMPLEX VIRUS, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240287014
    Abstract: A biflavone compound against an I-type herpes simplex virus, and a preparation method therefor and the use thereof. The bioflavone compound is a compound of formula I, or a crystal form thereof, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a hydrate thereof, or a prodrug thereof. The biflavone compound has a good inhibitory effect on the I-type herpes simplex virus, has a significant effect on the replication and direct inactivation of the virus, and is dose dependent. The compound is also effective in preventing and/or treating viral keratitis caused by the I-type herpes simplex virus. The compound has good water solubility and low toxicity. It can be prepared into an external preparation for resisting the I-type herpes simplex virus, such as eye drops and eye ointment, and external ointments, creams, gel agents, film agents, film-coating agents, etc.
    Type: Application
    Filed: August 22, 2022
    Publication date: August 29, 2024
    Inventors: Lei ZHANG, Chongjun YUAN, Mingming YUAN, Shuai CHEN, Wei YANG, Sen LUO, Xia WU
  • Isoflavone derivatives of tectorigenin, the preparation thereof and the antiviral medicine containing the same as an effective constituent
    Patent number: 7902253
    Abstract: An isoflavone derivative of tectorigenin compound as shown in formula (II), its preparation method and the antiviral medicine containing it as an effective constituent. The compound structure is shown as follows: Where:: R1 is H, NH2 or SO3M; R2 is OR?; R3 is H or —CH2NR?; where R? is H, —CH2COONa or —CH2CH2NMe2; NR? is or —NMe2; M is H, Na, K or N+H (CH2CH2OH)3.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: March 8, 2011
    Assignees: Chengdu Dikang Pharmaceutical Institute, Sichuan Dikang Sci-Tech Pharmaceutical Co., Ltd.
    Inventors: Xuemin Xu, Chongjun Yuan, Jia Wang, Shangbin Qi, Hai Yin, Yanming Zeng
  • Isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as an effective constituents
    Publication number: 20070123566
    Abstract: An isoflavone derivative of tectorigenin compound as shown in formula (II), its preparation method and the antiviral medicine containing it as an effective constituent. The compound structure is shown as follows: Where:: R1 is H, NH2 or SO3M; R2 is OR?; R3 is H or —CH2NR?; where R? is H, —CH2COONa or —CH2CH2NMe2; NR? is or —NMe2; M is H, Na, K or N+H (CH2CH2OH)3.
    Type: Application
    Filed: May 14, 2004
    Publication date: May 31, 2007
    Applicants: CHENGDU DIKANG PHARMACEUTICAL INSTITUTE, SICHUAN DIKANG SCI-TECH PHARMACEUTICAL CO., LTD.
    Inventors: Xuemin Xu, Chongjun Yuan, Jia Wang, Shangbin Oi, Hai Yin, Yanming Zeng